secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001157523-23-001659
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024
--------------------------------------------------------------------------------

- Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.
- Cash, equivalents, and short-term investments $106.3M at Sep 30, down 45% from $193.4M at Dec 31, 2022.
- Total revenue Q3 $24.3M, up 7% YoY; driven by non-cash royalty revenue of $20.4M.
- BLA submission for botensilimab/BAL in MSS CRC planned mid-2024; milestone payment from BMS partnership expected by end of 2023.
- Pursuing non-dilutive financing: selling non-strategic assets and partial milestone/royalty sales, expected to close by H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323001659/0001157523-23-001659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000115752323001659/a53764435.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer